Literature DB >> 7509816

Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice.

Y Kitamura1, Y Itano, T Kubo, Y Nomura.   

Abstract

Systemic injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is known to damage the dopaminergic nigrostriatal system in C57BL/6 mice. We have investigated the effects of immunosuppressants, FK-506 and cyclosporin A (CsA), on MPTP-induced dopamine (DA) depletion in the striatum of young C57BL/6 mice. 10 days after MPTP treatment (25 mg/kg i.p. given daily, 5 days), DA in the striatum was depleted by 80%. However, pretreatment with FK-506, a novel immunosuppressant, significantly protected MPTP-induced DA depletion in the striatum, but FK-506 itself did not affect the DA content. CsA, another immunosuppressant, also protected MPTP-induced DA depletion. From these results can be seen that immunosuppressants seem to inhibit MPTP neurotoxicity toward nigrostriatal dopaminergic neurons of young C57BL/6 mice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7509816     DOI: 10.1016/0165-5728(94)90049-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

1.  Strategies for the protection of dopaminergic neurons against neurotoxicity.

Authors:  M Gerlach; K L Double; M B Youdim; P Riederer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

3.  Age-related changes of sodium-dependent D-[3H]aspartate and [3H]FK506 binding in rat brain.

Authors:  T Araki; H Kato; K Shuto; T Fujiwara; Y Itoyama
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 4.  The future use of complement inhibitors for the treatment of neurological diseases.

Authors:  E G McGeer; P L McGeer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

5.  Calcineurin determines toxic versus beneficial responses to α-synuclein.

Authors:  Gabriela Caraveo; Pavan K Auluck; Luke Whitesell; Chee Yeun Chung; Valeriya Baru; Eugene V Mosharov; Xiaohui Yan; Manu Ben-Johny; Martin Soste; Paola Picotti; Hanna Kim; Kim A Caldwell; Guy A Caldwell; David Sulzer; David T Yue; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-13       Impact factor: 11.205

Review 6.  Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support.

Authors:  Samuel E Marsh; Mathew Blurton-Jones
Journal:  Neurochem Int       Date:  2017-02-20       Impact factor: 3.921

7.  Post-ischemic alterations in [3H]FK506 binding in the gerbil and rat brains.

Authors:  T Araki; H Kato; K Shuto; Y Itoyama
Journal:  Metab Brain Dis       Date:  1998-03       Impact factor: 3.584

8.  Increases in [3H]FK-506 and [3H]L-N(G)-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation.

Authors:  T Araki; H Tanji; K Fujihara; H Kato; Y Itoyama
Journal:  Metab Brain Dis       Date:  1999-03       Impact factor: 3.584

9.  Neuroprotective mechanisms of antiparkinsonian dopamine D2-receptor subfamily agonists.

Authors:  Yoshihisa Kitamura; Takashi Taniguchi; Shun Shimohama; Akinori Akaike; Yasuyuki Nomura
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

Review 10.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.